Ei­sai’s US chair, glob­al Alzheimer’s leader to re­tire weeks af­ter Leqem­bi ap­proval

Ivan Che­ung, the glob­al leader of Ei­sai’s Alzheimer’s ap­pa­ra­tus, will re­tire at the end of Ju­ly, the Japan­ese drug­mak­er said Tues­day, just four days af­ter the biotech and its part­ner Bio­gen se­cured full ap­proval for Leqem­bi.

Tak­ing his place is Ei­sai CEO Haruo Naito’s son Keisuke Naito, who will add the act­ing glob­al Alzheimer’s post to his ex­ist­ing du­ties as chief strat­e­gy and plan­ning of­fi­cer and chief ecosys­tem of­fi­cer.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER